all product development documents generated by formulation development, analytical R&D, regulatory affairs, process engineering, and associated functions involved in the development of sterile injectable products, from concept to technology transfer and regulatory submission.

3. Responsibilities

• Formulation Scientists: Document formulation trials, batch records, and stability protocols.
• Analytical Scientists: Maintain method development, validation records, and testing logs.
• Regulatory Affairs: Prepare summaries for submission (e.g., CTD Modules 2 and 3).
• Process Development: Document scale-up, equipment selection, and process optimization trials.
• QA (Quality Assurance): Review, archive, and ensure Good Documentation Practices (GDP).

4. Accountability

The Head of Formulation Development is accountable for the accuracy and timely generation of development documentation. QA Head ensures adherence to GDP and regulatory audit readiness.

5. Procedure

5.1 Good Documentation Practices (GDP)

1. All entries shall be made in permanent ink (blue or black) with legible handwriting.
2. No overwriting. Corrections must be made by striking through with a single line, initialing, and dating.
3. Each page shall bear the document number, version, and pagination.
4. Signatures must include full name, date, and designation.

5.2 Types of Documents

1. Development Protocols: Outline the objective, methodology, and acceptance criteria for each study.
2. Trial Batch Records: Record material quantities, equipment used, environmental parameters, and deviations.
3. Method Development Reports: Document selection of analytical technique, optimization steps, and robustness findings.
4. Stability Study Reports: Include study design, conditions (25°C/60%RH, 5°C, 40°C/75%RH), and data interpretation.
5. Scale-Up and Tech Transfer Reports: Provide process reproducibility, equipment matching, and yield justification.

5.3 Document Numbering System

1. Assign unique identification codes to each document as follows:
   • FD/PROT/YYYY/NNN for protocols
   • FD/TRIAL/YYYY/NNN for trial batch records
   • FD/ANALYT/YYYY/NNN for analytical reports
   • FD/REG/YYYY/NNN for regulatory summaries

5.4 Document Review and Approval

1. Documents must be reviewed by the respective department head and checked by QA.
2. Final approval is required by QA Head before archival or regulatory submission.
3. Maintain Document Approval Form (Annexure-1) for each document set.

5.5 Document Storage and Retention

1. Store all records in secure, access-controlled cabinets or digital DMS systems.
2. Retain physical records for at least 5 years after product discontinuation or as per regulatory guidance.
3. Electronic records must comply with 21 CFR Part 11 for audit trails and data integrity.

5.6 Template Usage

1. Use standard templates for consistency across documentation:
   • Formulation Development Template
   • Trial Batch Record Template
   • Analytical Method Template
2. All templates to be controlled under Master Template Index (Annexure-2).

5.7 Audit and Control

1. QA shall conduct periodic audits (quarterly) on a minimum of 10% of documentation generated.
2. Findings to be recorded in Documentation Audit Log (Annexure-3).

6. Abbreviations

• SOP: Standard Operating Procedure
• GDP: Good Documentation Practices
• DMS: Document Management System
• QA: Quality Assurance
• CTD: Common Technical Document

7. Documents

1. Document Approval Form – Annexure-1
2. Master Template Index – Annexure-2
3. Documentation Audit Log – Annexure-3

8. References

• WHO TRS 996 Annex 7 – Good documentation practices
• ICH Q8(R2) – Pharmaceutical Development
• 21 CFR Part 11 – Electronic records and signatures

9. SOP Version

Version: 2.0

10. Approval Section

	Prepared By	Checked By	Approved By
Signature
Date
Name
Designation	Formulation Scientist	QA Executive	Head QA
Department	Formulation Development	Quality Assurance	Quality Assurance

11. Annexures

Annexure-1: Document Approval Form

Document Title	Doc ID	Prepared By	Checked By	Approved By
Stability Protocol for PFS	FD/PROT/2025/031	Sunita Reddy	Rajesh Kumar	Dr. Meera Joshi

Annexure-2: Master Template Index

Template Name	Template ID	Version	Effective Date
Trial Batch Record	TMP/FDBR/01	1.2	01/03/2025

Annexure-3: Documentation Audit Log

Date	Auditor	Document Audited	Findings	Corrective Action
05/06/2025	Vinay Pawar	Trial Batch Record – TBR/042	Signature missing on page 3	Signature completed post-audit

Revision History

Revision Date	Revision No.	Details	Reason	Approved By
10/05/2022	1.0	Initial release	First version of SOP	Head QA
24/06/2025	2.0	Included Annexures and Template Index	Annual Review	Head QA